Fluxion Expands Into Asia With First China Sale, Distributors in Korea and Japan
News Dec 07, 2009
A second agreement with Novel Science covers sales of both the BioFlux and IonFlux™ platforms in Japan. Fluxion has also sold its first BioFlux 1000 system into China. The China Academy of Chinese Medical Science will initially use this system for research on inhibition of thrombus formation on endothelial cells.
Fluxion’s BioFlux instruments enable live cell image analysis for physiologically-relevant shear flow assays in a standard well-plate format. Ideal applications include research in cell and platelet adhesion, cancer biology, stem cells and microbial biofilms. The IonFlux line combines Fluxion’s proprietary microfluidic technology with integrated electronics to automate the traditional patch clamp assay, the “gold standard” in ion channel research. Ideal drug discovery applications include primary/secondary screening, lead optimization and toxicology screening.
DI Biotech Ltd. is headquartered in Seoul, Korea, and has a branch office in Daejeon City. DI Biotech has been a market leader and pioneer in Korea's Life Science market. The company works closely with its customers, with a focus on genomics, molecular biology, peptide synthesis and cell imaging. S. E. Kim, CEO and President at D.I Biotech comments, “Awareness of the importance of shear stress is increasing among researchers. The static biological method will move toward more dynamic assays using shear stress control to get closer in vivo data. I am delighted to introduce technology from Fluxion Bioscience to the Korean market and to our customers in cell biology research.”
Unraveling How Mesenchymal Stem Cells From Gum Tissue Accelerate Wound HealingNews
To assist with wound healing, mesenchymal stem cells from the gum tissue secrete extracellular vesicles that contain the anti-inflammatory signaling molecule IL-1RA.READ MORE
'Body-on-a-Chip' Could Advance Drug EvaluationNews
MIT engineers have developed new technology that could be used to evaluate new drugs and detect possible side effects before the drugs are tested in humans. Using a microfluidic platform that connects engineered tissues from up to 10 organs, the researchers can accurately replicate human organ interactions for weeks at a time.READ MORE
Hope for Hot Flushes: New Class of Menopause Drugs Reduces SeverityNews
A new class of experimental drugs reduces hot flushes in menopausal women by almost three-quarters in just three days. The new analysis, published in the journal Menopause, also revealed sleep and concentration significantly improved in the three-day window.